Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Organon & Co. (OGN)
Company Research
Source: Business Wire
The American Academy of Dermatology (AAD) provided a strong, evidence-based recommendation for the use of VTAMA cream, the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence that is indicated across all severities in children aged 2 years and older with atopic dermatitis (AD)This recommendation reflects the proven efficacy, safety, and tolerability of VTAMA cream as a first-in-class, steroid-free, topical aryl hydrocarbon receptor (AhR) agonist for children and adolescents with ADAD, the most common form of eczema, impacts nearly 10 million children in the US JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that VTAMA cream was granted a strong, evidence-based recommendation by the American Academy of Dermatology (AAD) in their 2026 guidelines for the management and treatment of atopic dermatitis (A
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- The 10 Healthcare stocks with the lowest forward P/E ratios [Seeking Alpha]Seeking Alpha
- Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026Business Wire
- Organon & Co. (OGN) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
- Why Organon (OGN) Is Surging as Buyout Interest Gains Traction [Yahoo! Finance]Yahoo! Finance
- Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health GrantsPR Newswire
OGN
Earnings
- 2/12/26 - Miss
OGN
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- OGN's page on the SEC website